Effect of Circulating Soluble Receptor for Advanced Glycation End Products (sRAGE) and the Proinflammatory RAGE Ligand (EN-RAGE, S100A12) on Mortality in Hemodialysis Patients | Zendy

Ayumu Nakashima | Zendy; Juan Jesús Carrero | Zendy; Abdul Rashid Qureshi | Zendy; Tetsu Miyamoto | Zendy; Björn Anderstam | Zendy; Peter Bárány | Zendy; Olof Heimbürger | Zendy; Peter Stenvinkel | Zendy; Bengt Lindholm | Zendy

Open Access

Effect of Circulating Soluble Receptor for Advanced Glycation End Products (sRAGE) and the Proinflammatory RAGE Ligand (EN-RAGE, S100A12) on Mortality in Hemodialysis Patients

Author(s) -

Ayumu Nakashima,

Juan Jesús Carrero,

Abdul Rashid Qureshi,

Tetsu Miyamoto,

Björn Anderstam,

Peter Bárány,

Olof Heimbürger,

Peter Stenvinkel,

Bengt Lindholm

Publication year - 2010

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.03360410

Subject(s) - medicine , proinflammatory cytokine , glycation , hemodialysis , rage (emotion) , hazard ratio , inflammation , dialysis , prospective cohort study , c reactive protein , gastroenterology , endocrinology , confidence interval , receptor , neuroscience , biology

The soluble receptor of advanced glycation end products (sRAGE) may exert anti-inflammatory protective roles on the vasculature. In contrast, the RAGE ligand S100A12 (also known as EN-RAGE) contributes to inflammation and the development of atherosclerosis in animal models. Whether alterations at this level contribute to the increased mortality observed in patients on dialysis is currently unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research